FDA Accepts Supplemental Application for Teplizumab to Delay Stage 3 Type 1 Diabetes in Children Aged 1 Year and Older
The US Food and Drug Administration has accepted for Priority Review a supplemental biologic license application for Tzield (teplizumab-mzwv) to expand its age indication to include children as young as…